caa a22 4500 605535264 CHVBK 20210128100846.0 cr unu---uuuuu 210128e20151001xx s 000 0 eng 10.1007/s10517-015-3067-6 doi (NATIONALLICENCE)springer-10.1007/s10517-015-3067-6 Anxiolytic and Antidepressant Effects of Divaza and Brizantin [Elektronische Daten] [N. Yakovleva, T. Voronina, N. Suslov, I. Ertuzun, G. Molodavkin, V. Poseva, V. Andreeva, Yu. Dugina, M. Putilovskii, O. Epshtein] The anxiolytic and antidepressant activities of complex preparations divaza and brizantin containing antibodies to brain-specific protein S100 were estimated using Vogel conflict test and Nomura forced swimming test. Course treatment (5 days) of brizantin in a dose of 2.5 ml/kg and divaza in a dose of 7.5 ml/kg significantly increased punished drinking in the Vogel conflict test in comparison with the control. Both drugs also improved general emotional behavior during training prior to the test procedure. Brizantin and divaza in a dose of 7.5 ml/kg increased the number of wheel revolutions in the Nomura forced swimming test in comparison with the control; the effect of divaza was more pronounced. High correlation coefficients between the number of wheel revolutions during the first and second 5-min sessions are also indicative of antidepressant action of divaza and brizantin. Springer Science+Business Media New York, 2015 divaza nationallicence brizantin nationallicence S100 nationallicence anxiolytic effect nationallicence antidepressant effect nationallicence Yakovleva N. Materia Medica Holding, Moscow, Russia aut Voronina T. Materia Medica Holding, Moscow, Russia aut Suslov N. E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk, Russia aut Ertuzun I. Materia Medica Holding, Moscow, Russia aut Molodavkin G. Materia Medica Holding, Moscow, Russia aut Poseva V. Materia Medica Holding, Moscow, Russia aut Andreeva V. Materia Medica Holding, Moscow, Russia aut Dugina Yu Materia Medica Holding, Moscow, Russia aut Putilovskii M. Materia Medica Holding, Moscow, Russia aut Epshtein O. Materia Medica Holding, Moscow, Russia aut Bulletin of Experimental Biology and Medicine Springer US; http://www.springer-ny.com 159/6(2015-10-01), 753-756 0007-4888 159:6<753 2015 159 10517 https://doi.org/10.1007/s10517-015-3067-6 text/html Onlinezugriff via DOI BK010053 XK010053 XK010000 Metadata rights reserved Springer special CC-BY-NC licence nationallicence 1 research-article jats NATIONALLICENCE NATIONALLICENCE NL-springer NATIONALLICENCE 856 40 https://doi.org/10.1007/s10517-015-3067-6 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Yakovleva N. Materia Medica Holding, Moscow, Russia aut NATIONALLICENCE 700 1- Voronina T. Materia Medica Holding, Moscow, Russia aut NATIONALLICENCE 700 1- Suslov N. E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk, Russia aut NATIONALLICENCE 700 1- Ertuzun I. Materia Medica Holding, Moscow, Russia aut NATIONALLICENCE 700 1- Molodavkin G. Materia Medica Holding, Moscow, Russia aut NATIONALLICENCE 700 1- Poseva V. Materia Medica Holding, Moscow, Russia aut NATIONALLICENCE 700 1- Andreeva V. Materia Medica Holding, Moscow, Russia aut NATIONALLICENCE 700 1- Dugina Yu Materia Medica Holding, Moscow, Russia aut NATIONALLICENCE 700 1- Putilovskii M. Materia Medica Holding, Moscow, Russia aut NATIONALLICENCE 700 1- Epshtein O. Materia Medica Holding, Moscow, Russia aut NATIONALLICENCE 773 0- Bulletin of Experimental Biology and Medicine Springer US; http://www.springer-ny.com 159/6(2015-10-01), 753-756 0007-4888 159:6<753 2015 159 10517